Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000;2000(2):CD001971.
doi: 10.1002/14651858.CD001971.

Vancomycin for prophylaxis against sepsis in preterm neonates

A P Craft  1 , N N Finer, K J Barrington
Affiliations

Vancomycin for prophylaxis against sepsis in preterm neonates

A P Craft et al. Cochrane Database Syst Rev. 2000.

Abstract

Background: Nosocomial, late onset sepsis occurs in up to 50% of infants of less than 1000gm at birth. The commonest organism isolated is coagulase negative staphylococcus (CoNS). A number of studies have evaluated the efficacy or prophylactic low dose vancomycin given either as a continuous infusion added to the infant's hyperalimentation fluid or by intermittent intravenous administration and these studies in very low birth weight infants are the subject of this review.

Objectives: To evaluate the safety and efficacy of vancomycin prophylaxis for the prevention of late-onset sepsis, coagulase negative staphylococcal sepsis, mortality, and effects on length of stay, total vancomycin exposure, evidence of vancomycin toxicity, and the development of vancomycin resistant organisms in the preterm neonate.

Search strategy: Searches were made of Medline, (MeSH terms: Vancomycin and Sepsis; limits: age groups, newborn infants), HealthStar and EMBase, electronic abstracts, personal files and conference proceedings.

Selection criteria: Randomized controlled trials which compared the incidence of sepsis and mortality in preterm neonates receiving vancomycin prophylaxis versus a control group receiving no prophylaxis.

Data collection and analysis: Data regarding clinical outcomes including the overall incidence of sepsis, the incidence of coagulase negative staphylococcal sepsis, mortality, length of stay, total vancomycin exposure, evidence of vancomycin toxicity, and the development of vancomycin resistant organisms were excerpted from previous clinical trials. Data analysis was done in accordance with the standards of the Cochrane Neonatal Review Group.

Main results: The administration of prophylactic vancomycin reduced the incidence of both total neonatal nosocomial sepsis and coagulase negative staphylococcal sepsis in eligible preterm infants. Mortality, length of stay, and evidence of vancomycin toxicity were not significantly different between the two groups. There was insufficient evidence to ascertain the risks of development of vancomycin resistant organisms in the nurseries involved in these trials.

Reviewer's conclusions: The use of prophylactic vancomycin in low doses reduces the incidence of nosocomial sepsis in the neonate. The methodologies of these studies may have contributed to the low rate of sepsis in the treated groups, as the blood cultures drawn from central lines may have failed to grow due to the low levels of vancomycin in the infusate. Although there is a theoretical concern regarding the development of resistant organisms with the administration of prophylactic antibiotic, there is insufficient evidence to ascertain the risks of development of vancomycin resistant organisms. Few clinically important benefits have been demonstrated for very low birth weight infants treated with prophylactic vancomycin. It therefore appears that routine prophylaxis with vancomycin should not be undertaken at present.

PubMed Disclaimer

Conflict of interest statement

None

Figures

1.1
1.1. Analysis
Comparison 1 Vancomycin versus control, Outcome 1 Incidence of sepsis (all pathogens); number of patients with one or more episodes.
1.2
1.2. Analysis
Comparison 1 Vancomycin versus control, Outcome 2 Incidence of CoNS sepsis; number of patients with one or more episodes.
1.3
1.3. Analysis
Comparison 1 Vancomycin versus control, Outcome 3 Mortality prior to hospital discharge.
1.4
1.4. Analysis
Comparison 1 Vancomycin versus control, Outcome 4 Length of NICU stay (days).
1.5
1.5. Analysis
Comparison 1 Vancomycin versus control, Outcome 5 Hearing impairment (auditory brainstem evoked response).
See this image and copyright information in PMC

References

References to studies included in this review

Baier 1998 {published data only}
    1. Baier RJ, Bocchini JA, Brown EG. Selective use of vancomycin to prevent coagulase negative staphylococcal nosocomial bacteremia in high risk very low birth weight infants. Pediatric Infectious Disease Journal 1998;17:179‐83. - PubMed
Cooke 1997 {published data only}
    1. Cooke RWI, Nycyk JA, Okuonghuae H, Shah V, Damjanovic V, Hart CA. Low dose vancomycin prophylaxis reduces coagulase negative staphylococcal bacteraemia in very low birthweight infants. Journal of Hospital Infection 1997;37:297‐303. - PubMed
Kacica 1994 {published data only}
    1. Kacica MA, Horgan MJ, Ochoa L, Sandler R, Lepow ML, Venezia RA. Prevention of gram positive sepsis in neonates weighing less than 1500 grams. Journal of Pediatrics 1994;125:253‐8. - PubMed
Moller 1993 {published data only}
    1. Moller JC, Rossa M, Nachtrodt G, Richter A, Tegtmeyer FK. Praventive antibiotikagabe zur verhinderung nosokomialer septikamien bei sehr kleinen fruhgeborenen (VLBW Infants).. Klinische Padiatrie 1993;205:140‐4. - PubMed
Spafford 1994 {published data only}
    1. Spafford PS, Sinkin RA, Cox C, Reubens L, Powell KR. Prevention of central venous catheter related coagulase negative staphylococcal sepsis in neonates. Journal of Pediatrics 1994;125:259‐63. - PubMed

References to studies excluded from this review

Marchand 1990 {published data only}
    1. Marchand S, Poisson D, Borderon JC, Gold F, Chantepie A, Saliba E, Laugier J. Randomized study of vancomycin pharyngeal instillation as a prophylaxis of bronchopulmonary infection in intubated neonates. Biology of the Neonate 1990;58:521‐6. - PubMed
Ocete 1998 {published data only}
    1. Ocete E, Ruiz‐Extremera A, Goicoechea A, Lozano E, Robles C, Rey ML, et al. Low‐dosage prophylactic vancomycin in central‐venous catheters for neonates. Early Human Development 1998;53:S181‐6. - PubMed

Additional references

Ballow 1986
    1. Ballow M, Cates KL, et al. Development of the immune system in very low birth weight (less than 1500 g) premature infants: concentrations of plasma immunoglobulins and patterns of infections. Pediatric Research 1986;20:899‐904. - PubMed
Barefield 1994
    1. Barefield ES, Philips JB. Vancomycin prophylaxis for coagulase‐negative staphylococcal bacteremia. Journal of Pediatrics 1994;125:230‐2. - PubMed
Bhatt‐Mehta 1999
    1. Bhatt‐Mehta V, Schumacher RE, Faix RG, Leady M, Brenner T. Lack of vancomycin‐associated nephrotoxicity in newborn infants: A case‐ control study. Pediatrics 1999;103:e48. - PubMed
Carratala 1999
    1. Carratala J, Niubo J, Fernandez‐Sevilla A, Juve E, et al. Randomized, double‐blind trial of an antibiotic‐lock technique for prevention of gram‐positive central venous catheter‐related infection in neutropenic patients with cancer. Antimicrob Agents Chemother 1999;43:2200‐4. - PMC - PubMed
CDC 2002
    1. Center for Disease Control. Guidelines for the prevention of intravascular catheter related infections 2002. MMWR Recommendations and Reports 2002;51(RR‐10):10. - PubMed
Drossou 1997
    1. Drossou V, Kanakoudi F, Tzimouli V, Sarafidis K, Taparkou A, Bougiouklis D, et al. Impact of prematurity, stress and sepsis on the neutrophil respiratory burst activity of neonates. Biology of the Neonate 1997;72:201‐9. - PubMed
Gaynes 1995
    1. Gaynes RP, Horan TC. Definitions of nosocomial infections. In: Mayhall CG editor(s). Hospital Epidemiology and Infection Control. Baltimore, MD: Williams and Wilkins, 1995:Chap 77, Appendix A1.
Insoft 1996
    1. Insoft RM, Sanderson IR, Walker WA. Development of immune function in the intestine and its role in neonatal diseases. Pediatric Clinics of North America 1996;43:551‐71. - PubMed
Johnson‐Robbins 1996
    1. Johnson‐Robbins LA, El‐Mohandes AE, Simmens SJ. Staphylococcus epidermidis sepsis in the intensive care nursery: a characterization of risk associations in infants <1,000 g. Biology of the Neonate 1996;69:249‐56. - PubMed
Kallman 1998
    1. Kallman J, Schollin J, Schalen C, Erlandsson A, Kihlstrom E. Impaired phagocytosis and opsonisation towards group B streptococci in preterm neonates. Archives of Disease in Childhood. Fetal and Neonatal Edition 1998;78:F46‐F50. - PMC - PubMed
Matrai‐Kovalskis '98
    1. Matrai‐Kovalskis Y, Greenberg D, Shinwell ES, Fraser D, Dagan R. Positive blood cultures for coagulase‐negative staphylococci in neonates: does highly selective vancomycin usage affect outcome?. Infection 1998;26:85‐92. - PubMed
Moller 1997
    1. Moller JC, Nelskamp I, Jensen R, Reiss I, Kohl M, Gatermann S, et al. Comparison of vancomycin and teicoplanin for prophylaxis of sepsis with coagulase negative staphylococci (CONS) in very low birth weight infants. Journal of Perinatal Medicine 1997;25:361‐7. - PubMed
Nataro 1994
    1. Nataro JP, Corcoran L, Zirin S, et al. Prospective analysis of coagulase‐negative staphylococcal infection in hospitalized infants. Journal of Pediatrics 1994;125:798‐804. - PubMed
Patrick 1990
    1. Patrick CC. Coagulase‐negative staphylococci: Pathogens with increasing clinical significance. Journal of Pediatrics 1990;116:497‐507. - PubMed
Rutter 1996
    1. Rutter N. The immature skin. European Journal of Pediatrics 1996;155(2 Suppl):S18‐20. - PubMed
Stoll 1996
    1. Stoll BJ, Gordon T, Korones SB, et al. Late onset sepsis in very low birth weight neonates: A report from the National Institute of Child Health and Human Development Neonatal Research Network. Journal of Pediatrics 1996;129:63‐71. - PubMed

References to other published versions of this review

Craft 2000
    1. Craft AP, Finer NN, Barrington KJ. Vancomycin for prophylaxis against sepsis in preterm neonates. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD001971] - DOI - PMC - PubMed

Publication types

MeSH terms